He prescribes semaglutide and tirzepatide clinically and was one of the first physicians to publicly flag that 39% of weight loss from the STEP 1 trial was lean tissue

A range of disorders have been recognized: varying from psychomotor retardation in childhood, to intermittent neuropsychiatric disease with ataxia and other motor disabilities, such as Friedreich's and other spinocerebellar ataxias [70], as well as neural diseases where mental deficits are also visible such as Parkinson's disease, and Alzheimer's disease (AD) [70]In Parkinsons Disease which has been deeply investigated, KGDHC Activity is reduced, coupled to elevated levels of monoamine oxidase B [71] and cytosolic accumulation of cytochrome c which inturn activates other pathways, including cell death cascades and enzyme inhibition which alters Ca2+homeostasis [72] The KGDHC enzyme is further a target for ubiquitination-dependent degradation in mitochondria by binding of Siah2, the RING finger ubiquitin-protein isopeptide ligase 2, encoded by gene siah2 [73]

We next tested if the partial complementation of Taf12 depletion by ectopic expression of Taf12L-FLAG is due to incorporation of Taf12L-FLAG into TFIID complex
Thorough cost-benefit analysis helps ensure this investment aligns with personal health priorities, financial circumstances, and realistic outcome expectations
A Closer Look at Weight Loss Data Clinical trials have shown promising but varied weight loss outcomes